Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment.

Dan LiuXiyue XuYulian DaiXuan ZhaoShunshun BaoWen MaLi ZhaShuci LiuYuchen LiuJunnian ZhengNing Guo

Published in: Journal for immunotherapy of cancer (2021)

Our study implicates that CAR-T therapy combined with the blockade of AIM2 inflammasome or α1-AR may relieve IL-1β-related toxic side effects of CAR-T therapy and ensure antitumor effects of the treatment.

Keyphrases

adipose tissue
stem cells
mouse model
combination therapy
bone marrow